CSL Vifor has agreed to “quickly address" the competition issues surrounding Ferinject, U.K. authorities said in a release. (da-kuk/iStock/Getty Images Plus) After recently taking steps to undo ...

With a proposal to rectify disparaging messaging about the safety profile of a rival product, CSL Vifor hopes to avoid a fine and end a two-year antitrust investigation. (Vifor Pharma) CSL Vifor has ...

The UK Competition and Markets Authority (“CMA”) has recently published a decision accepting commitments from Vifor Pharma (“Vifor”). This brings to a close an unprecedented abuse of dominance ...

Pharma company Vifor promised to correct misleading information about a rival iron supplement’s safety record, following an EU antitrust investigation into abuse of a dominant market position.

Vifor Pharma has pledged to pay £23 million to the NHS after Britain’s competition watchdog raised concerns the drugs firm had been making misleading claims about the safety of a rival’s iron ...

Brussels: EU antitrust regulators on Monday accepted Australian group CSL unit Vifor Pharma's concessions to address potential anti-competitive behaviour towards a rival iron deficiency treatment ...

This article is brought to you by our exclusive subscriber partnership with our sister title USA Today, and has been written by our American colleagues. It does not necessarily reflect the view of The ...